Published in Medical Letter on the CDC and FDA, July 16th, 2000
To determine the cost-effectiveness of hepatitis A vaccine among U.S. children, A.S. Meyerhoff and colleagues from Capitol Outcomes Research, Inc., in Alexandria, Virginia, and the U.S. Centers for Disease Control and Prevention in Atlanta, Georgia, designed a model to assess the lifetime HAV incidence of "a single birth cohort with and without vaccination."
They presented the study results at the 10th International Symposium on...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.